Company / Cash & Equivalents
Sight Sciences, Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$92.0M
FY2025
5-year range
$92.0M / $260.7M
FY2021-FY2025
Trend
-23.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $261M in FY2021 to $92M in FY2025.
Based on SEC 10-K filings.
$92M in FY2025 with a 3-year CAGR of -20.8%.
Declined from $138M to $92M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -20.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Sight Sciences, Inc.'s cash & equivalents has declined for 4 consecutive years.
- 3-year CAGR of -20.8%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 23.6% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $92.0M | -23.6% |
| FY2024 | $120.4M | -12.9% |
| FY2023 | $138.1M | -25.3% |
| FY2022 | $185.0M | -29.0% |
| FY2021 | $260.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026